Pfizer to Buy Hospira for $15 Billion as Drug Maker Looks to Expand Revenues

Pfizer said on Thursday that it would pay $90 a share for Hospira, which makes infusion technologies and drugs that are injected. Including debt, the deal is valued at about $17 billion.

“The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and [earnings per share] growth in the near term,” Ian Read, Pfizer’s chief executive, said in a statement.

Subscribe

Follow

The New York Times